Join Clinical Trials in Oklahoma for Allergies

All Categories Medical Conditions » Allergies » Oklahoma

A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)

Condition: Asthma
Interventions: Drug: MEMP1972A; Drug: MEMP1972A; Drug: MEMP1972A; Drug: placebo
Sponsors: Genentech; Genentech
Not yet recruiting - verified April 2012
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

Condition: Asthma
Interventions: Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4; Other: Placebo DPI; Drug: Flovent Diskus 250 mcg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Not yet recruiting - verified May 2012
A Study of ARRY-502 in Patients With Persistent Asthma

Condition: Asthma
Interventions: Drug: ARRY-502, CRTh2 antagonist; oral; Drug: Placebo; oral
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified May 2012
A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)

Condition: Asthma
Interventions: Drug: lebrikizumab; Drug: lebrikizumab; Drug: lebrikizumab; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
Relief of Acute Bronchoconstriction/Asthma Using the Non-Invasive AlphaCore Device

Conditions: Bronchoconstriction; Asthma
Intervention: Device: The AlphaCore Device
Sponsors: ElectroCore LLC; ElectroCore LLC
Recruiting - verified February 2012
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab; Drug: Matching Placebo
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

Condition: Asthma
Interventions: Drug: Placebo; Drug: Flovent Diskus; Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; PPD
Recruiting - verified May 2012
A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3)

Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug: Mometasone Furoate MDI 100 mcg; Drug: Mometasone Furoate MDI 200 mcg; Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug: Prednisone/prednisolone
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).

Conditions: Perennial Allergic Rhinitis; PAR
Interventions: Drug: Ciclesonide nasal aerosol 37 mcg; Drug: ciclesonide nasal aerosol 74 mcg; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified March 2012
A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Condition: Asthma
Interventions: Drug: Symbicort pMDI; Drug: Symbicort pMDI; Drug: budesonide pMDI; Drug: budesonide pMDI
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012
Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma

Condition: Asthma
Interventions: Drug: Fluticasone furoate 50mcg; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Dose Finding Study for QAW039 in Asthma

Condition: Asthma
Interventions: Drug: QAW039; Drug: Comparator leukotriene receptor antagonist (LRTA); Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Efficacy, Safety, and Tolerability of SAR231893(REGN668) in Patients With Persistent Moderate to Severe Eosinophilic Asthma

Condition: Asthma
Interventions: Biological: SAR231893 (REGN668); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified April 2012
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations and Change in Lung Function in Patients (12-75 Years of Age) With Eosinophilic Asthma

Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab; Drug: Placebo
Sponsors: Cephalon; Cephalon
Recruiting - verified April 2012
Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma

Condition: Asthma
Interventions: Drug: tiotropium Respimat low dose; Drug: tiotropium Respimat high dose; Drug: placebo Respimat
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified May 2012
A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo

Condition: Asthma
Interventions: Drug: budesonide; Drug: placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2012
Patient Registry Study of Berinert® in Normal Clinical Practice

Condition: Includes: Hereditary Angioedema
Intervention: Biological: Berinert® (C1 Esterase Inhibitor)
Sponsors: CSL Behring; CSL Behring; Chiltern International Inc.
Recruiting - verified May 2012
Elitek (Rasburicase) Immuno-Monitoring Study

Condition: Tumor Lysis Syndrome
Intervention:
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified February 2012
Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema

Condition: Hereditary Angioedema
Intervention: Drug: ecallantide
Sponsors: Dyax Corp.; Dyax Corp.
Recruiting - verified April 2012
A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma

Condition: Asthma
Interventions: Drug: Levalbuterol; Drug: Levalbuterol UDV TID; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified February 2012
A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis

Condition: Atopic Dermatitis
Intervention:
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified March 2012